论文部分内容阅读
目的：探讨急性髓细胞白血病（ＡＭＬ）血瘀型与非血瘀型的关系，并为ＡＭＬ血瘀型辨证论治提供客观指标。方法：按中医辨证分型的原则，将５６例ＡＭＬ患者分为血瘀型（２４例）与非血瘀型（３２例）２组，用间接免疫法，观察ＣＤ＋２、ＣＤ＋４、ＣＤ＋８、ＣＤ＋１０、ＣＤ＋１４、ＣＤ＋１５、ＣＤ＋１９在２组患者的表达情况。结果：血瘀型ＡＭＬ患者髓系分化抗原ＣＯ＋１４为６９．６１±２．２１，ＣＤ＋１９为８０．２０±２．１１；淋系分化抗原ＣＤ＋２为３０．４１±３．２２，ＣＤ＋４为２６．１２±４．１８，ＣＤ＋８为１９．０４±２．６１。非血瘀型患者髓系分化抗原ＣＤ＋１４为７１．０５±２．６６，ＣＤ＋１９为７９．６１±１．０２；淋系分化抗原ＣＤ＋２为２７．６２±２．４１，ＣＤ＋４为２４．１１±３．２１，ＣＤ＋８为１７．６２±１．１０。且用标准的ＤＡ、ＨＡ方案治疗２个疗程后，血瘀型治愈７例，好转７例，无效１０例，总有效率５８．３％。而非血瘀型治愈１０例，好转１２例，无效１０例，总有效率６８．８％。非血瘀型疗效明显优于血瘀型组（Ｐ＜０．０５）。结论：血瘀型ＡＭＬ患者淋系与髓系分化抗原均有高表达，治疗效果也较差。因此，可将ＡＭＬ患者有淋系分?
Objective: To investigate the relationship between blood stasis type and non-blood stasis type in acute myeloid leukemia (AML), and provide objective indicators for AML blood stasis type syndrome differentiation and treatment. Methods: According to the principle of TCM syndrome differentiation, 56 patients with AML were divided into two groups: blood stasis type (24 cases) and non-bloody stasis type (32 cases). CD+2, CD+4, CD+8, and CD+10 were observed by indirect immunoassay. CD+14, CD+15, CD+19 expression in two groups of patients. RESULTS: The myeloid differentiation antigen CO+14 was 69.61±2.21, CD+19 was 80.20±2.11, the lymphoid differentiation antigen CD+2 was 30.41±3.22, and the CD+4 was 26.12. ±4.18, CD+8 was 19.04±2.61. The myeloid differentiation antigen CD+14 in non-blood group patients was 71.05±2.66, CD+19 was 79.61±1.02, the lymphoid differentiation antigen CD+2 was 27.62±2.41, and CD+4 was 24.11±3. .21, CD+8 was 17.62±1.10. After two courses of treatment with standard DA and HA regimens, 7 cases were cured with blood stasis, 7 cases improved, and 10 cases were ineffective. The total effective rate was 58.3%. Instead of bloody type, 10 cases were cured, 12 cases were improved, 10 cases were ineffective, and the total effective rate was 68.8%. The effect of non-blood stasis type was obviously better than that of blood stasis type group (P<0.05). CONCLUSIONS: Leukemia and myeloid differentiation antigens are highly expressed in patients with hemorrhagic AML, and the therapeutic effect is also poor. Therefore, patients with AML can have a leucine fraction?